
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SET7/9 CRISPR/Cas9 KO Plasmid (r) | sc-437354 | 20 µg | $397.00 |
SET7/9 (also known as SETD7) is a lysine methyltransferase that predominantly catalyzes monomethylation of histone H3 at Lys4 (H3K4me1) and can also modify non-histone substrates, shaping transcriptional outputs and protein stability. In rat cells, SET7/9 activity integrates with chromatin remodeling to regulate cell-cycle control, differentiation programs, and stress-responsive gene expression. Through methylation-dependent crosstalk with pathways linked to p53 signaling and NF-κB–associated inflammatory transcription, SET7/9 influences genome maintenance and stimulus-induced transcriptional dynamics. Dysregulated SET7/9 function has been associated with epigenetic alterations relevant to cancer biology, metabolic and cardiovascular phenotypes, and inflammatory disease models, supporting its use as a mechanistic node in epigenetics research.
SET7/9 CRISPR/Cas9 KO Plasmid (r) is a pool of plasmids designed for targeted disruption of the gene in rat cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SET7/9 protein expression.
This CRISPR knockout system enables efficient generation of -deficient cell models for investigation of SET7/9 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.